Immune System News and Research

RSS

Scientists discover new mechanism that explains role of EBV in tumor growth

The Epstein-Barr virus (EBV), a virus of the herpes family, has two distinct life phases: After infecting a cell it first goes into a resting phase. Under certain circumstances the virus can become active - and then induces tumor growth or promotes its synthesis in the cell.

18 Jan 2010

Scientists manipulate and expand the number of stem/progenitor cells

Scientists at Fred Hutchinson Cancer Research Center have cleared a major technical hurdle to making umbilical-cord-blood transplants a more widely-used method for treating leukemia and other blood cancers.

18 Jan 2010

U.S. DOD awards LUHS $1.6M to continue burn research

Loyola University Health Systems (LUHS) has received a $1.6 million contract from the U.S. Department of Defense (DOD) to research burn injuries, the care of burn wounds and infections and how burns affect the immune system.

18 Jan 2010

FDA admits concern, but does not ban BPA: Consumers Union disappointed

Consumers Union, the nonprofit publisher of Consumer Reports, expressed disappointment with the U.S. Food & Drug Administration's (FDA) failure to ban the chemical bisphenol A (BPA), despite announcing today that there is cause for concern over its potential effect on children. Consumers Union believes that that there is enough scientific evidence to date to warrant a ban on BPA in food contact products now.

18 Jan 2010

New study indicates a decline in biomedical research; Autism Speaks urges government to increase research funding

As the Journal of the American Medical Association (JAMA) reports on the actual decline in U.S. biomedical research funding, Autism Speaks, the nation's largest autism science and advocacy organization, again called on the federal government to immediately step up its efforts - and dramatically increase research funding - to address the growing national autism public health crisis.

18 Jan 2010

M. D. Anderson researchers discover mechanism that helps glioblastomas evade immune attack

Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumor, also suppress an immune system attack on the disease, scientists from The University of Texas M. D. Anderson Cancer Center report in a paper featured on the cover of the Jan. 15 issue of Clinical Cancer Research.

18 Jan 2010

New findings may yield novel therapies for chronic neurodegenerative diseases

We all have at one time or another experienced the typical signs of an infection: the fever, the listlessness, the lack of appetite. They are orchestrated by the brain in response to circulating cytokines, the signaling molecules of the immune system. But just how cytokines' reach extends beyond the almost impenetrable blood-brain barrier has been the topic of much dispute.

18 Jan 2010

AVIR Green Hills Biotechnology commences deltaFLU Phase II study

AVIR Green Hills Biotechnology, the innovative biotech company based in Vienna, has started the New Year by embarking on the first clinical phase II study for the seasonal vaccine deltaFLU. The study will be carried out at the Medical University of Vienna. With this step, AVIR Green Hills has set yet another important milestone in the development of effective and modern influenza vaccines.

18 Jan 2010

Study raises concerns about drug-resistant HIV

The emergence of drug-resistant strains of HIV could one day threaten efforts to control the global HIV pandemic, according to a study published online Thursday in the journal Science, HealthDay News/U.S. News & World Report reports. The researchers based their findings on "a mathematical model that tracks the transmission of multiple strains of HIV" in San Francisco, the news service writes (1/14).

18 Jan 2010

Early immune response needed for 'hit-and-hide' cancer viruses

Retroviruses such as HIV and HTLV-1 don't hit-and-run, they hit-and-hide. They slip into host cells and insert their own DNA into the cell's DNA, and from this refuge they establish an infection that lasts a lifetime.

14 Jan 2010

Multimmune GmbH and Boulder Diagnostics partner to develop HSP70 lateral flow point of care test

Multimmune GmbH and Boulder Diagnostics Inc. announce today the joint development of an HSP70 lateral flow point of care test. Multimmune has discovered that many tumor types display the heat shock protein 70 (Hsp70) on the cell surface.

13 Jan 2010

Obesity could lead to renal cell cancer: BJUI

Being obese could lead to a greater risk of developing the most common form of renal cell cancer, according to research in the January issue of the UK-based urology journal BJUI.

13 Jan 2010

University of Leicester study provides new insights into preventer and reliever treatments for asthma

A new study at the University of Leicester is probing why asthma relief inhalers might actually make asthma worse- and what can be done about it.

13 Jan 2010

Research reveals how cancers shield themselves from immune attack

Melanoma, if not detected in its early stages, transforms into a highly deadly, treatment-resistant cancer. Although the immune system initially responds to melanoma and mounts anti-tumor attacks, these assaults are generally ineffective, allowing more advanced melanomas to win the battle and spread beyond the primary site.

13 Jan 2010

TTI enters into definitive license agreement with Biogen Idec

Trillium Therapeutics Inc. , a biopharmaceutical company developing innovative immune-based biologics, today announced that it has entered into a definitive license agreement with Biogen Idec , granting the latter exclusive worldwide rights to one of Trillium's development programs.

12 Jan 2010

AMA awards unique CPT code for Cylex' ImmuKnow assay

Cylex Incorporated® announced today that the American Medical Association (AMA) CPT Editorial Panel approved the creation of new CPT coding based on the uniqueness, clinical value and widespread use of ImmuKnow, and the fact that existing CPT codes insufficiently captured all steps and costs of testing.

12 Jan 2010

VaxInnate grants license to Biological E. to develop and commercialize recombinant H1N1 vaccine in India

VaxInnate Corporation today announced that it has granted Indian biopharmaceutical company Biological E. Limited a license to its recombinant H1N1 pandemic swine flu vaccine and is collaborating to facilitate the manufacture, clinical development and commercialization of the vaccine in India.

12 Jan 2010

Phase I clinical trial of XRX-001 for yellow fever initiated

Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.

12 Jan 2010

Cytheris commences enrollment in its recombinant human Interleukin-7 INSPIRE 2 program for HIV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 2, a Phase IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non Responders (INR) after at least 12 months of highly active anti-retroviral therapy (HAART).

12 Jan 2010

MRCT announces licensing deal for development of novel therapy for inflammatory and immune diseases

Georg-August-University Gottingen, University of Regensburg and MRC Technology (MRCT) have signed exclusive license agreements through MBM ScienceBridge GmbH and in agreement with Bayerische Patentallianz GmbH, for the development of a novel therapy of inflammatory and immune diseases based on the depletion of inflammatory monocytes. The first targets will be rheumatoid arthritis (RA) and multiple sclerosis (MS).

12 Jan 2010

Immune System News and Research

Scientists discover new mechanism that explains role of EBV in tumor growth

Scientists manipulate and expand the number of stem/progenitor cells

U.S. DOD awards LUHS $1.6M to continue burn research

FDA admits concern, but does not ban BPA: Consumers Union disappointed

New study indicates a decline in biomedical research; Autism Speaks urges government to increase research funding

M. D. Anderson researchers discover mechanism that helps glioblastomas evade immune attack

New findings may yield novel therapies for chronic neurodegenerative diseases

AVIR Green Hills Biotechnology commences deltaFLU Phase II study

Study raises concerns about drug-resistant HIV

Early immune response needed for 'hit-and-hide' cancer viruses

Multimmune GmbH and Boulder Diagnostics partner to develop HSP70 lateral flow point of care test

Obesity could lead to renal cell cancer: BJUI

University of Leicester study provides new insights into preventer and reliever treatments for asthma

Research reveals how cancers shield themselves from immune attack

TTI enters into definitive license agreement with Biogen Idec

AMA awards unique CPT code for Cylex' ImmuKnow assay

VaxInnate grants license to Biological E. to develop and commercialize recombinant H1N1 vaccine in India

Phase I clinical trial of XRX-001 for yellow fever initiated

Cytheris commences enrollment in its recombinant human Interleukin-7 INSPIRE 2 program for HIV

MRCT announces licensing deal for development of novel therapy for inflammatory and immune diseases

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News